[{"address1": "21 Business Park Drive", "city": "Branford", "state": "CT", "zip": "06405", "country": "United States", "phone": "203 646 6446", "website": "https://azitrainc.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.", "fullTimeEmployees": 10, "companyOfficers": [{"maxAge": 1, "name": "Mr. Francisco D. Salva", "age": 52, "title": "President, CEO & Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 427030, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark  Sampson", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.47, "open": 1.31, "dayLow": 1.282, "dayHigh": 1.46, "regularMarketPreviousClose": 1.47, "regularMarketOpen": 1.31, "regularMarketDayLow": 1.282, "regularMarketDayHigh": 1.46, "volume": 15999, "regularMarketVolume": 15999, "averageVolume": 28933, "averageVolume10days": 101670, "averageDailyVolume10Day": 101670, "bidSize": 1100, "askSize": 800, "marketCap": 16089809, "fiftyTwoWeekLow": 0.92, "fiftyTwoWeekHigh": 5.18, "priceToSalesTrailing12Months": 25.682058, "fiftyDayAverage": 1.2953, "twoHundredDayAverage": 2.125225, "currency": "USD", "enterpriseValue": 12648739, "floatShares": 2917589, "sharesOutstanding": 12097600, "sharesShort": 6665, "sharesShortPriorMonth": 9208, "sharesShortPreviousMonthDate": 1702598400, "dateShortInterest": 1705017600, "sharesPercentSharesOut": 0.00059999997, "heldPercentInsiders": 0.17994, "heldPercentInstitutions": 0.62949, "shortRatio": 0.29, "shortPercentOfFloat": 0.00059999997, "impliedSharesOutstanding": 12097600, "bookValue": 0.441, "priceToBook": 3.015873, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -14924166, "trailingEps": -1.23, "enterpriseToRevenue": 20.19, "enterpriseToEbitda": -1.663, "52WeekChange": -0.6711409, "SandP52WeekChange": 0.20233083, "exchange": "ASE", "quoteType": "EQUITY", "symbol": "AZTR", "underlyingSymbol": "AZTR", "shortName": "Azitra Inc", "longName": "Azitra, Inc.", "firstTradeDateEpochUtc": 1687267800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "e7445f64-9918-3241-b1f1-a0f95f2c4b08", "messageBoardId": "finmb_404021170", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.33, "targetHighPrice": 5.0, "targetLowPrice": 5.0, "targetMeanPrice": 5.0, "targetMedianPrice": 5.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 4400327, "totalCashPerShare": 0.364, "ebitda": -7604685, "totalDebt": 959201, "quickRatio": 3.064, "currentRatio": 3.346, "totalRevenue": 626500, "debtToEquity": 17.989, "revenuePerShare": 0.151, "returnOnAssets": -0.57408, "returnOnEquity": -3.7964, "freeCashflow": -4846601, "operatingCashflow": -6951654, "revenueGrowth": 5.406, "grossMargins": 1.0, "operatingMargins": -6.4169, "financialCurrency": "USD", "trailingPegRatio": null}]